PositiveID Corporation retains Secure Strategy Group
PositiveID is the developer of airborne biological agent detection systems for the U.S. homeland security defense industry. It also develops and produces rapid medical testing devices. The company's wholly owned subsidiary, Microfluidic Systems, focuses on the development and performance of automated biological testing devices to detect threats in high-value locations.
"We are pleased to work closely with SSG, which has a strong track record assisting companies that address critical needs for homeland security," William J. Caragol, the chairman and CEO of PositiveID, said. "The team at SSG includes leaders experienced in securing federal government and commercial opportunities, and we believe that by working together, PositiveID will be able to increase value for our stockholders."
Secure Strategy Group is a strategic advisory practice specializing in the homeland security market. SSG analyzes industry, government and private sector initiatives in order to identify technologies that have potential for growth. The group's members have been involved in raising more than $50 billion in capital for public and private technology companies.
"PositiveID is at an exciting turning point in its evolution," SSG President Scott Greiper said. "As PositiveID completes the re-positioning of its business, its homeland defense technology fulfills an important and unmet market need. Through our extensive relationships and industry knowledge we believe we can accelerate PositiveID's ability to achieve its goals and capitalize on new initiatives."